Form 4 for IMVT Immunovant, Inc.
Accepted 2025-04-11 00:00:00 ET · period of report 2025-04-09 · accession 0001764013-25-000066 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-11 | 2025-04-09 | IMVT | Salzmann Peter | CEO, Dir | S - Sale | $12.99 | -28.1K | 1.19M | -2% | -$364.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-09 | S | D | 28,094 | $12.99 | 1,186,512 | D | — | — | (F1) On April 2, 2024, the holder was granted 160,534 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 40,133 of these RSUs vested on April 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |